Agilex expands bioanalytical labs capacity to meet US, APAC demand

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/marchmeena29)
(Image: Getty/marchmeena29)

Related tags: expansion, facility, Australia, Bioanalytical

Agilex has expanded its bioanalytical laboratories by 30%, in order to accommodate demand coming mainly from US and APAC-based biotech companies.

Australia-based Agilex Biolabs is a contract research organization (CRO) providing bioanalytical services for researchers at early stages of clinical development, supporting clients in Asia, Europe and the US.

Per its services, the company focuses on bioanalysis for small molecules and biologics for pharmacokinetics, immunogenicity and biomarkers, utilizing two platforms that conduct liquid chromatography, mass spectrometry, and immunoassays.

The expansion will see Agilex’s facilities located in a biotech hub in Adelaide, South Australia grow by 30%, enabling the company to include a range of additional pharmacodynamics services​ in its offering.

According to the company, the Adelaide laboratory is the only FDA-inspected facility of its type in the region.

Agilex’s CEO, Jason Valentine, said that the facility employs more than 65 dedicated laboratory staff, working to support more than 80 clinical trials every year.

“This year we will analyze more than 60,000 samples for pharma and biotechs from the US, Europe and APAC,”​ said Valentine, adding that, to date, the company has supported hundreds of preclinical and clinical trials around the world.

Amid the ongoing coronavirus pandemic, the company announced that it will be offering virtual tours in the expanded laboratories.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more